
Opinion|Videos|January 28, 2025
Overview of the ENRICH Study
Panelists discuss the ENRICH study, focusing on the efficacy and safety of enzalutamide in combination with standard therapies for metastatic castration-resistant prostate cancer and its potential to improve progression-free survival.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5








































